{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:10:20Z","timestamp":1792894220174,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec id=\"ab-irv260003-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Continuous glucose monitoring (CGM), initially recommended primarily for people with type 1 diabetes, has rapidly expanded to patients with type 2 diabetes and, more recently, even to individuals without diabetes. This broadening use underscores the importance of critically examining the evidence supporting CGM across populations, clarifying where benefits are established, where they are modest, and where they remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-irv260003-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      We reviewed systematic reviews and meta-analyses of randomized trials and clinical guidelines evaluating CGM use beyond type 1 diabetes, with particular attention to glycemic outcomes, hypoglycemia, patient-reported outcomes, and potential unintended consequences in nonpregnant adults. In adults with type 2 diabetes, evidence from randomized trials consistently demonstrated that CGM use was associated, on average, with a modest yet consistent reduction in hemoglobin A\n                      <jats:sub>1c<\/jats:sub>\n                      of approximately 0.3% compared with finger-stick monitoring or usual care; some patients benefited considerably more. Only limited and indirect evidence supported the adoption of CGM in people with type 2 diabetes not receiving glucose-lowering therapy or in those with prediabetes or obesity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-irv260003-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>CGM should be deployed in response to a specific patient problem rather than as a default intervention. Deliberate, equitable deployment of CGM that is aligned with patient goals, clinical context, and system capacity will be necessary to ensure that those most likely to benefit are not left behind, while avoiding overuse in populations for whom benefit remains unproven.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2026.2772","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:00:54Z","timestamp":1785769254000},"page":"1166","source":"Crossref","is-referenced-by-count":1,"title":["Continuous Glucose Monitoring in Type 2 Diabetes and Beyond"],"prefix":"10.1001","volume":"186","author":[{"given":"Justin A.","family":"Dower","sequence":"first","affiliation":[{"name":"Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Johansson","sequence":"additional","affiliation":[{"name":"General Practice, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Global Center for Sustainable Healthcare, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne W.","family":"Camp","sequence":"additional","affiliation":[{"name":"Fair Haven Community Health Care, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Montori","sequence":"additional","affiliation":[{"name":"Knowledge and Evaluation Research Unit, Division of Endocrinology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia J.","family":"Lipska","sequence":"additional","affiliation":[{"name":"Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"irv260003r2","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.2337\/dc08-S012","article-title":"Standards of medical care in diabetes\u20142008.","volume":"31","author":"American Diabetes Association","year":"2008","journal-title":"Diabetes Care"},{"key":"irv260003r3","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.2337\/dc26-S007","article-title":"7. Diabetes technology: standards of care in diabetes\u20142026.","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","journal-title":"Diabetes Care"},{"issue":"12","key":"irv260003r5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"issue":"6","key":"irv260003r7","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.mcna.2021.06.004","article-title":"Continuous glucose monitoring for the internist.","volume":"105","author":"Lee","year":"2021","journal-title":"Med Clin North Am"},{"issue":"6","key":"irv260003r9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/dia.2018.0364","article-title":"Lag time remains with newer real-time continuous glucose monitoring technology during aerobic exercise in adults living with type 1 diabetes.","volume":"21","author":"Zaharieva","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"irv260003r10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1177\/1932296815580160","article-title":"Analytical performance requirements for systems for self-monitoring of blood glucose with focus on system accuracy: relevant differences among ISO 15197:2003, ISO 15197:2013, and current FDA recommendations.","volume":"9","author":"Freckmann","year":"2015","journal-title":"J Diabetes Sci Technol"},{"issue":"4","key":"irv260003r11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1177\/193229681100500419","article-title":"Efficacy of continuous glucose monitoring in improving glycemic control and reducing hypoglycemia: a systematic review and meta-analysis of randomized trials.","volume":"5","author":"Gandhi","year":"2011","journal-title":"J Diabetes Sci Technol"},{"key":"irv260003r12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1758-5996-5-39","article-title":"Systematic review and meta-analysis of the effectiveness of continuous glucose monitoring (CGM) on glucose control in diabetes.","volume":"5","author":"Poolsup","year":"2013","journal-title":"Diabetol Metab Syndr"},{"issue":"9","key":"irv260003r13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1089\/dia.2018.0177","article-title":"The effectiveness of continuous glucose monitoring in patients with type 2 diabetes: a systematic review of literature and meta-analysis.","volume":"20","author":"Park","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"9","key":"irv260003r14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5634","article-title":"Continuous glucose monitoring versus self-monitoring of blood glucose in type 2 diabetes mellitus: a systematic review with meta-analysis.","volume":"11","author":"Janapala","year":"2019","journal-title":"Cureus"},{"issue":"1","key":"irv260003r15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-001092","article-title":"Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis.","volume":"8","author":"Castellana","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"irv260003r16","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.2337\/dc19-1459","article-title":"Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials.","volume":"43","author":"Maiorino","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"irv260003r17","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/dom.14981","article-title":"Professional continuous glucose monitoring in patients with diabetes mellitus: a systematic review and meta-analysis.","volume":"25","author":"Di Molfetta","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"irv260003r18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/dia.2023.0390","article-title":"Continuous glucose monitoring systems in noninsulin-treated people with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","volume":"26","author":"Ferreira","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"irv260003r19","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s00125-024-06107-6","article-title":"Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis.","volume":"67","author":"Jancev","year":"2024","journal-title":"Diabetologia"},{"issue":"1","key":"irv260003r20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/dom.15328","article-title":"Effects of continuous glucose monitoring on glycaemic control in type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.","volume":"26","author":"Lu","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"irv260003r21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12966-024-01692-6","article-title":"The efficacy of using continuous glucose monitoring as a behaviour change tool in populations with and without diabetes: a systematic review and meta-analysis of randomised controlled trials.","volume":"21","author":"Richardson","year":"2024","journal-title":"Int J Behav Nutr Phys Act"},{"issue":"1","key":"irv260003r22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2337\/dc23-1520","article-title":"Efficacy and safety of continuous glucose monitoring and intermittently scanned continuous glucose monitoring in patients with type 2 diabetes: a systematic review and meta-analysis of interventional evidence.","volume":"47","author":"Seidu","year":"2024","journal-title":"Diabetes Care"},{"issue":"4","key":"irv260003r23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1210\/clinem\/dgad652","article-title":"Effectiveness of continuous glucose monitoring on metrics of glycemic control in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.","volume":"109","author":"Uhl","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"irv260003r24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/dia.2024.0599","article-title":"Continuous glucose monitoring in type 1 diabetes, type 2 diabetes, and diabetes during pregnancy: a systematic review with meta-analysis of randomized controlled trials.","volume":"27","author":"Rizos","year":"2025","journal-title":"Diabetes Technol Ther"},{"issue":"11","key":"irv260003r25","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.1111\/dom.70008","article-title":"Continuous glucose monitoring in noninsulin-treated type 2 diabetes: a critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trials.","volume":"27","author":"Aronson","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"irv260003r26","doi-asserted-by":"publisher","DOI":"10.1177\/19322968251384318","article-title":"Continuous glucose monitoring to guide lifestyle choices with a focus on nutrition in the management of type 2 diabetes: a systematic review and meta-analysis.","author":"Bannuru","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"23","key":"irv260003r30","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.3390\/nu16234005","article-title":"Enhancing the impact of individualized nutrition therapy with real-time continuous glucose monitoring feedback in overweight and obese individuals with prediabetes.","volume":"16","author":"Basiri","year":"2024","journal-title":"Nutrients"},{"issue":"5","key":"irv260003r31","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1089\/dia.2022.0544","article-title":"Discordance between glucose management indicator and glycated hemoglobin in people without diabetes.","volume":"25","author":"Shah","year":"2023","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"irv260003r32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41591-020-0934-0","article-title":"Human postprandial responses to food and potential for precision nutrition.","volume":"26","author":"Berry","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"irv260003r33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.orcp.2025.10.003","article-title":"Understanding the benefits and psychological burdens of using continuous glucose monitoring for lifestyle change: a mixed-methods cross-sectional study.","volume":"19","author":"Richardson","year":"2025","journal-title":"Obes Res Clin Pract"},{"issue":"1","key":"irv260003r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpdig.2024.11.001","article-title":"Digital medicine tools and the work of being a patient: a qualitative investigation of digital treatment burden in patients with diabetes.","volume":"3","author":"Al Zahidy","year":"2024","journal-title":"Mayo Clin Proc Digit Health"},{"issue":"1","key":"irv260003r35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/19322968231183974","article-title":"Treatment satisfaction and well-being with continuous glucose monitoring in people with type 1 diabetes: an analysis based on the GOLD randomized trial.","volume":"19","author":"Pylov","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"2","key":"irv260003r36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s11606-013-2595-x","article-title":"Pitfalls in hemoglobin A1c measurement: when results may be misleading.","volume":"29","author":"Radin","year":"2014","journal-title":"J Gen Intern Med"},{"issue":"5","key":"irv260003r37","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70057","article-title":"Recommendations for the management of diabetes during Ramadan applying the principles of the ADA\/ EASD consensus: update 2025.","volume":"41","author":"Ibrahim","year":"2025","journal-title":"Diabetes Metab Res Rev"},{"key":"irv260003r38","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.diabres.2019.03.015","article-title":"The use of Free Style Libre Continues Glucose Monitoring (FSL-CGM) to monitor the impact of Ramadan fasting on glycemic changes and kidney function in high-risk patients with diabetes and chronic kidney disease stage 3 under optimal diabetes care.","volume":"151","author":"Alawadi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"24","key":"irv260003r39","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1001\/jama.2025.19197","article-title":"Continuous glucose monitoring.","volume":"334","author":"Bergenstal","year":"2025","journal-title":"JAMA"},{"issue":"11","key":"irv260003r40","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.2337\/dc18-1581","article-title":"Glucose Management Indicator (GMI): a new term for estimating A1C from continuous glucose monitoring.","volume":"41","author":"Bergenstal","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"irv260003r41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/19322968231200901","article-title":"Minimum sampling duration for continuous glucose monitoring metrics to achieve representative glycemic outcomes in suboptimal continuous glucose monitor use.","volume":"19","author":"Akturk","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"4","key":"irv260003r42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00592-019-01446-y","article-title":"\u201cOut of the box\u201d solution for skin problems due to glucose-monitoring technology in youth with type 1 diabetes: real-life experience with fluticasone spray.","volume":"57","author":"Paret","year":"2020","journal-title":"Acta Diabetol"},{"issue":"5","key":"irv260003r43","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/15209156251395034","article-title":"Multivendor continuous glucose monitor integration into the electronic health record: real-world experience of an academic pediatric endocrinology clinic.","volume":"28","author":"Knopp","year":"2026","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"irv260003r44","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1177\/19322968231178549","article-title":"The need for data standards and implementation policies to integrate insulin delivery data into the electronic health record.","volume":"17","author":"Espinoza","year":"2023","journal-title":"J Diabetes Sci Technol"},{"issue":"11","key":"irv260003r45","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1089\/dia.2024.0083","article-title":"Assessing patterns of continuous glucose monitoring use and metrics of glycemic control in type 1 diabetes and type 2 diabetes patients in the veterans health care system: integrating continuous glucose monitoring device data with electronic health records data.","volume":"26","author":"Okuno","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"8","key":"irv260003r46","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2337\/dca25-0006","article-title":"Overall uptake and racial, ethnic, and socioeconomic disparities in the use of continuous glucose monitoring devices among insulin-treated older adults with type 2 diabetes.","volume":"48","author":"Alkabbani","year":"2025","journal-title":"Diabetes Care"},{"issue":"11","key":"irv260003r47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.45316","article-title":"Disparities in continuous glucose monitoring among patients receiving care in federally qualified health centers.","volume":"7","author":"Wallia","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"12","key":"irv260003r48","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1089\/dia.2024.0152","article-title":"Association of race and ethnicity with prescriptions for continuous glucose monitoring systems among a national sample of veterans with diabetes on insulin therapy.","volume":"26","author":"Lipska","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"irv260003r49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/bmjebm-2021-111871","article-title":"Making care fit manifesto.","volume":"28","author":"Kunneman","year":"2023","journal-title":"BMJ Evid Based Med"},{"key":"irv260003r1","unstructured":"Innovation milestones. Medtronic. December 14, 2012. Accessed June 23, 2026. https:\/\/origin.medtronicdiabetes.com\/about-medtronic-innovation\/milestone-timeline"},{"key":"irv260003r4","unstructured":"Type 2 diabetes in adults: management. National Institute for Health and Care Excellence. December 2, 2015. Accessed December 13, 2025. https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/Recommendations-for-research"},{"key":"irv260003r6","unstructured":"FDA clears first over-the-counter continuous glucose monitor. US Food and Drug Administration. March 5, 2024. Accessed December 14, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-over-counter-continuous-glucose-monitor"},{"key":"irv260003r8","unstructured":"Integrated continuous glucose monitoring system. 21 CFR \u00a7862.1355 (2022). Accessed February 10, 2026. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-H\/part-862\/subpart-B\/section-862.1355"},{"key":"irv260003r27","unstructured":"Kee? C. Can continuous glucose monitors help with weight loss? experts weigh in. TODAY.com. September 12, 2025. Accessed December 13, 2025. https:\/\/www.today.com\/health\/diet-fitness\/cgm-for-weight-loss-rcna229869"},{"key":"irv260003r28","unstructured":"How one woman changed her life using a glucose monitor. Good Morning America. August 29, 2024. Accessed December 13, 2025. https:\/\/www.goodmorningamerica.com\/video\/113236337"},{"key":"irv260003r29","unstructured":"New continuous glucose monitoring innovation\u2014Dr. Casey Means. Levels. May 31, 2021. Accessed December 15, 2025. https:\/\/www.levels.com\/podcasts\/new-continuous-glucose-monitoring-innovation-dr-casey-means"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2851941\/jamainternal_dower_2026_rv_260003_1788184604.17789.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:01:06Z","timestamp":1788879666000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2851941"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2026.2772","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}